Pfizer Inc

Pfizer’s post‑COVID pivot: how oncology, obesity and potential M&A moves reshape its market‑access, patent and risk profile.

Pfizer’s 2026 guidance signals flat revenue but tighter costs, while $900 million licensing deals with Adaptive Biotechnologies boost its autoimmune pipeline—balancing steady earnings with targeted growth.

Pfizer cuts Swiss staff, sees cost savings, boosts margins; phase‑III study shows Tukysa extends survival for HER2‑positive breast cancer, while a new GLP‑1 partnership targets fast‑track obesity treatment.

Pfizer’s $2 billion deal with YaoPharma for a small‑molecule GLP‑1 obesity drug and strong Phase 3 hemophilia data shows a strategic shift toward cost‑effective, globally‑scalable therapies.

Pfizer’s Phase 3 haemophilia A trial shows a 68 % drop in bleeding events with once‑weekly PF‑N8‑A, while its new GLP‑1 and CAR‑T drugs promise expanded oncology and obesity portfolios.

Pfizer’s 2035 U.S. dollar bond at 4.875% shows strong debt‑to‑EBITDA and cash‑flow coverage, yet faces patent cliffs and competition—read how it can exploit oncology growth and strategic partnerships to stay ahead.

Pfizer’s neutral outlook: stable share price, rising institutional interest, and a pipeline of key candidates—don’t miss the December webcast for crucial clinical and regulatory updates.

Pfizer’s Q3 2025 earnings show a 3.8 % revenue dip but beat EPS estimates, thanks to cost discipline and a growing specialty drug focus, while the Metsera bid and tightening drug‑pricing regulations pose key risks and opportunities for investors.

Pfizer Inc. is navigating a complex landscape of opportunity and risk, with its stock performance and valuation influenced by factors such as its robust pipeline, litigation exposure, regulatory developments, and global trade policies.

Pfizer Inc. has announced its acquisition of Metsera, a biotechnology company focused on anti-obesity therapies, in a deal valued at $47.50 per share with potential upside to $70 per share, marking Pfizer’s first significant transaction in two years…